Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.

lutetium Lu 177 rofapitide tetraxetan (AAA614) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42223513

Ajit H Goenka; Arnaud Demange; Burcu Babaoglan; Jonathan McConathy; Jordi Rodon; Lars Blumenstein; Paola Aimone; Ryan H Moy; Sophie Morse; Thomas A Hope; Vadim S Koshkin; Yusuf Menda

Jun 2, 2026